Zydus receives USFDA's final approval for Indomethacin Suppository with competitive generic therapy designation
Zydus' Indomethacin suppositories also been granted 180-day CGT exclusivity to market this product.
Zydus' Indomethacin suppositories also been granted 180-day CGT exclusivity to market this product.
Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy
Proposed acquisition represents meaningful step forward in Biogen’s strategy for sustainable growth
Unfortunate to see PM’s ‘Make in India’ dream being bulldozed
Marks the World Head & Neck Cancer Day at the OCTF Conference
Preclina is renowned for its highly specialized services in autoimmune and inflammatory disorders
Zurletrectinib was developed to treat advanced or metastatic solid tumors harboring NTRK fusion genes
Tiotropium (as bromide monohydrate) 18 micrograms powder for inhalation in capsule
The approval allows treatment of heart failure patients irrespective of the ejection fraction based on new trial DELIVER conducted by AstraZeneca
Subscribe To Our Newsletter & Stay Updated